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A B S T R A C T
Objective: To analyze the clinical and autonomic profile of patients with Alzheimer’s disease 
or mixed dementia (MD). 
Methods: Fifty-four patients with indication for cholinesterase inhibitors use were evaluated 
through clinical examination, rest electrocardiogram, and spectral analysis of heart rate (HR) 
variability through digital Holter system recordings.
Results: Overall, 61.1% of patients were females and were, on average, 77.1 years of age, had 
3.3 years of schooling, and scored 16.4 points on the Mini Mental State Examination. The 
gap between symptom onset and diagnosis was 26.2  months. Almost all patients (90.7%) 
presented at least one clinical comorbidity, and each patient took, on average, 3.7 drugs to 
control them. Thirty-one patients had some alteration on the electrocardiogram, and nine 
(16.6%) had orthostatic hypotension (OH). The latter was associated with the diagnosis of 
MD (p =  0.001), with lower values of low (LF) and high (HF) frequency components of the 
spectral analysis in the supine position (p = 0.000 and p = 0.017, respectively), and with lower 
values of  LF in the orthostatic position (p =  0.006). Diagnosis of MD was associated with 
lower values of LF in both positions (p = 0.003 and p = 0.007). 
Conclusion: This sample of patients had frequent comorbidities, which resulted in the 
prescription of multiple drugs. Signs of autonomic dysfunction resulting in OH were found 
mainly in those with MD.
© 2012 Elsevier Editora Ltda.  Este é um artigo Open Access sob a licença de CC BY-NC-ND
Este é um artigo Open Access sob a licença de CC BY-NC-ND
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Perfil clínico e autonômico de pacientes com doença de Alzheimer 
e demência mista
R E S U M O 
Objetivo: Analisar o perfil clínico e a atividade autonômica de pacientes com diagnóstico de 
doença de Alzheimer ou demência mista (DM).
Métodos: Foram avaliados 54 pacientes com indicação de uso de inibidores da colinesterase, 
por meio de exame clínico, eletrocardiograma de repouso e da análise espectral da varia-
bilidade da frequência cardíaca (VFC).
Resultados: A casuística estudada, constituída por 61,1% de mulheres, apresentava média de 
77,1 anos de idade, 3,3 anos de escolaridade, pontuação de 16,4 no miniexame do estado 
mental e intervalo médio de 26,2 meses entre o início dos sintomas e o diagnóstico. A quase 
totalidade (90,7%) apresentava comorbidades, com o uso, em média, de 3,7 drogas/paciente. 
Trinta e um (57,4%) pacientes apresentavam alterações eletrocardiográficas e nove (16,6%), 
hipotensão ortostática (HO). Esta apresentou associação com o diagnóstico de DM (p = 0,001) 
e com valores mais baixos dos componentes de baixa (BF) e de alta (AF) frequência da VFC na 
posição supina (p = 0,000 e p = 0,017), além de valores médios menores de BF em ortostatismo 
(p =  0,006). O diagnóstico de DM se associou a menores valores de BF nas duas posições 
(p = 0,003 e p = 0,007). 
Conclusão: Na amostra estudada, a presença de comorbidades e o uso de vários fármacos 
foram frequentes. Foram observados sinais de disfunção autonômica, resultando em HO, 
principalmente nos pacientes com DM.
Introduction
The term dementia refers to an acquired clinical syndrome 
characterized by a group of signs and symptoms expressed by 
memory difficulties, language disorders, behavioral alterations, 
and deficits in activities of daily living.1 The most common causes 
are Alzheimer’s disease (AD) – accounting for 60% to 70% of the 
cases2 – vascular dementia (VD), and mixed dementia (MD), 
which is the combination of lesions resulting from the first two.3
The estimated overall prevalence of dementia is approxi-
mately 5% of those aged 65 or older,4 and a prevalence of 7.1% 
was found in a Brazilian study.5 It was estimated that, in 2005, 
there were approximately 24.3 million patients with dementia 
worlwide, a figure that could reach 81.1 million in 2040,6 and 
114 million in 2050.7 The annual treatment costs range between 
U$ 24.7 billion1 and U$ 83.9 billion8 in some countries, and 
personal costs (both for patients and for caregivers) and life 
years lost should also be taken into account.1
The diagnosis is attained by associating the clinical 
assessment to cognitive function tests and the differential 
diagnosis with other conditions. The cognitive function 
assessment often consists of the Mini Mental State Examination 
(MMSE) and tests for specific cognitive domains (e.g., memory 
and executive functions), when indicated.9
Healthy elderly individuals, due to degenerative alterations 
characteristic of the aging process, have increased prevalence 
of falls and other forms of neurovascular instability. This 
picture becomes more pronounced in the elderly with 
dementia, as degenerative alterations are more prominent and 
there is greater impairment of the structures involved in the 
autonomic nervous system (ANS) control.10
One way to study the ANS activity is through spectral 
analysis of heart rate variability (HRV), in which the variation 
of the interval between successive heart beats originates high 
and low frequency (HF and LF) bands, reflecting activation of 
the sympathetic and parasympathetic branches, respectively, 
in addition to allowing for the study of sympathovagal balance, 
through their ratio11 (LF/HF).
Comparing the incidence of fall-related injuries in healthy 
elderly individuals and AD patients, an odds ratio of 6.4 was 
observed for these injuries in individuals with the disease.12 
A prevalence of neurovegetative instability was also observed 
in 57% of patients with AD, i.e., orthostatic hypotension (OH), 
vasovagal syncope, and carotid sinus hypersensitivity.13
Several studies have been performed to assess the ANS 
functioning in AD and, in general, although the results are 
not fully in agreement, they are consistent with the presence 
of autonomic dysfunction. Aharon-Peretz et al.14 demonstrated 
exacerbation of the sympathetic system with relative 
depression of the parasympathetic system, while Vitiello 
et al.15 found a deficit of blood pressure response to the 
orthostatic position test in patients with AD. 
Another study demonstrated a decrease in parasympathetic 
function at rest and during deep breathing, as well as a 
preserved sympathetic response.10 Ferini-Strambi et al., 
studying HRV during sleep, found no change in vagal tone, 
but observed sympathetic dysfunction in over one third of 
patients with AD.16 Two studies from the same group of British 
researchers initially showed no difference between AD patients 
and control groups regarding the spectral analysis of HRV.17 
Subsequently, using other tools in addition to HRV to assess 
dysautonomia, the authors found a greater decrease in blood 
pressure (BP) during orthostasis in AD patients when compared 
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to controls, concluding that, apart from a higher prevalence 
of OH, patients with AD have relatively preserved autonomic 
function.18
In the scientific literature analyzed, the only study 
performed in a Brazilian population to assess the matter 
demonstrated a decrease in parasympathetic influence and 
relative sympathetic exacerbation in a group of 22 patients 
with AD. An increase in LF/HF ratio was observed in the 
supine position, indicating the sympathetic predominance in 
sympathovagal balance.19
The first cholinesterase inhibitor (ChEI) was approved in 
Brazil for the treatment of AD in 1994; those most often used 
in the present were introduced in the market in 1998, 2000, 
and 2001.20 Since these drugs have been introduced relatively 
recently in the market and are intended for use predominantly 
by the elderly – in whom the presence of comorbidities and 
polypharmacy is very common –, there is a great interest in 
studying the clinical profile and behavior of the ANS of the 
population to whom they are prescribed.
The present study aimed to analyze the clinical and ANS 
profile in patients with AD and MD who received an indication 
for ChEI use. 
Methods
This was a prospective, observational, cross-sectional study 
of 54 patients diagnosed with AD or MD, who were treated at 
the outpatient clinics of Cognitive Neurology and Geriatrics 
from the Hospital das Clínicas of the Universidade Federal de 
Minas Gerais (UFMG), and who had received an indication for 
ChEI use. 
Sample size calculation was conducted aiming to perform a 
longitudinal study to investigate the influence of ChEI on the 
autonomic profile in patients with AD or MD. For that purpose, 
the standard deviation of the high-frequency component of 
spectral analysis in the general population, the difference of 
at least 200 ms2 to be detected, and a power of test of 90%, 
with a significance level of 5%, were used for a one-tailed test. 
Thus, an estimate of 34 patients was obtained and, considering 
a ratio of 50% possible discontinuity due to adverse effects of 
the drug, the value obtained was of a minimum of 50 patients.
Patients were included in the study after a diagnosis of 
probable mild to moderate AD, according to the NINCDS-
ADRDA criteria,21 or AD with cerebrovascular disease (i.e., MD), 
according to the NINDS-AIREN criteria.22 For that purpose, the 
patients were submitted to extensive cognitive assessment 
that included the MMSE,23,24 functional evaluation through 
the Pfeffer questionnaire,25,26 the clock test,27,28 the picture 
memory test,29 the CERAD word list,30 biochemical tests (blood 
count, serum electrolytes, thyroid function, vitamin B12, 
among others), and neuroimaging (CT or MRI). 
Both the research project and the informed consent were 
approved by the Research Ethics Committee of UFMG. Patients 
were invited to participate in the study when they were treated 
at the clinic, and the inclusion was performed consecutively. 
Patients with severe dementia and who were clinically unstable 
at the time of evaluation, in addition to those with conditions 
that might interfere with or prevent the interpretation of HRV, 
such as atrial fibrillation, cardiac pacemaker rhythm, and use 
of antiarrhythmic drugs, except beta blockers, were excluded.
After acceptance to participate and signature of the 
informed consent by the patient or caregiver responsible (in 
case of patients with marked cognitive impairment), patients 
underwent clinical evaluation and a 12-lead electrocardiogram 
(ECG) assessment and digital monitoring by Holter system, in 
the morning. 
The ECG was performed with a Philips equipment, model 
Pagewriter Trim III (Philips Medical Systems – USA) at a 
speed of 50 mm/s and an amplitude of 20 mm/mV. Holter 
monitoring was performed using a Cardioflash® digital 
multi-cardiographer, three-channel model (modified V1 and 
V5 and D3), version 1.0, in the supine and orthostatic position 
during a period of 15 and 10 minutes, respectively, for HRV 
analysis. The latter was performed using the DMI/Burdick 
Holter analysis program (ALTAIRPC v6.00B Holter System), 
evaluating the spectral analysis, i.e., assessing the frequency 
domain by Fourier transformation, allowing measurements 
of the LF, HF components, and LF/HF ratio. The evaluation of 
such components was made after strict manual editing of the 
records, with artifact elimination and arrhythmia correction. 
The results of the spectral analysis were expressed in 
milliseconds squared (ms2).
Data analysis was carried out using the Statistical Package 
for the Social Sciences (SPSS), 12.0 version. The results 
were expressed in numbers and proportion, in the case of 
discrete variables, and as measures of central tendency 
(mean and median) and dispersion for continuous variables. 
The Mann-Whitney and Chi-squared or Fisher’s tests were 
used, when appropriate, to compare the differences between 
continuous and discrete variables, respectively. Spearman’s 
coefficient was used to verify the correlations between 
variables. The level of rejection of the null hypothesis was set 
at 0.05. 
Results
General sample characteristic
The mean age of patients was 77.1 ± 7.3 years (range 54-89), 
33 (61.1% of the sample) were females and 21 males; mean 
level of schooling was 3.3 ± 2.4 years. Thirty-nine patients had 
probable AD and 15 had probable MD, whose mean score at 
the MMSE was 16.4 ± 5.0 points. There was a mean interval of 
22.6 months between symptom onset and diagnosis. Family 
history of dementia was detected in 22 patients (40.7%). 
Regarding comorbidities, only five patients (9.2%) had 
no clinical comorbidities and received psychotropic drugs 
only to control the behavioral changes related to dementia. 
Among the others, the most frequent comorbidities were 
hypertension (62.9%), depression (20.3%), diabetes mellitus 
(16.7%), osteoporosis (9.2%), prostatic hyperplasia (9.2%), 
epilepsy (7.4%), chronic obstructive pulmonary disease/asthma 
(7.4%), hypothyroidism (7.4%), and chronic renal failure (5.5%).
For the management of these comorbidities, patients 
received therapeutic regimen with other drugs, on average, 
3.7 drugs each. Thirty-five patients (64%) used antihypertensive 
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drugs, of whom 13 received beta-blockers and 16 received 
angiotensin-converting enzyme inhibitors; hypoglycemic 
agents were used by seven patients, and psychotropic drugs – 
which included antidepressants, antipsychotics and especially 
benzodiazepines – were used by 32 patients (59%). 
The therapeutic regimen of five patients consisted of only 
one drug, 33 used between two to four drugs, and 16 used more 
than four drugs, including two patients using eight drugs each.
Clinical examination and orthostatic hypotension test
Clinical examination showed that nine (16.6%) patients had 
OH, defined as a decrease of at least 20 mmHg in systolic blood 
pressure (SBP) and/or 10 mmHg in diastolic blood pressure 
(DBP) after three minutes in the orthostatic position.31 The 
clinical data of the study population are shown in Table 1.
When analyzing the association between the presence of OH 
and clinical variables such as gender, age, anthropometric data, 
time since dementia diagnosis, family history of dementia, 
and type of dementia, a significant association was observed 
only with the latter. Among patients with OH, seven patients 
(46.6%) had MD and two patients (5.4%) had AD (p = 0.001). After 
applying Spearman’s correlation coefficient, the value 0.50 was 
obtained (p = 0.000) between these two variables.
Electrocardiogram
The ECG showed sinus rhythm in 50 patients; two were in atrial 
fibrillation, one had low atrial rhythm, and another patient had 
atrial flutter with a 4:1 atrioventricular conduction. Mean heart 
rate (HR) was 68.9 ± 14.4 bpm, ranging from 34 to 123 bpm. 
The electrocardiographic tracings of 23 patients showed no 
significant alterations, while the remaining 31 patients had 
electrocardiographic alterations, which are summarized in 
Table 2. 
Autonomic nervous system
Table 3 shows the values found when evaluating the ANS 
of 50 patients in sinus rhythm through spectral analysis, 
in the supine and standing positions. This table also shows 
the statistical treatment using the Wilcoxon test, comparing 
the values of LF and HF components and their association 
with change in position. Logarithmic conversion was also 
performed, maintaining the same p-values. 
There was no association between the spectral analysis 
components and gender. However, there was an association 
between this spectral analysis and the two types of demen-
tia. MD patients had a lower mean LF component in the 
supine position compared to AD patients (137.2 ms2 vs. 
385.1 ms2, p = 0.003), as well as lower mean LF component 
in the orthostatic position (124.8 ms2 vs. 426.7 ms2, p = 0.007). 
Regarding the HF component in the orthostatic position, the 
difference was borderline significant (p = 0.055). 
The spectral analysis between patients without and with 
OH showed lower values of the LF (360.3 ms2 and 26 ms2, 
respectively, p = 0.000) and HF (1,206.7 ms2 and 72.6 ms2, 
p = 0.017) components in the supine position in the second 
group. There was also mean lower LF component in the 
orthostatic position in that group (383.0 ms2 vs. 57.1 ms2, 
p = 0.006), with no significant difference in LF/HF ratio in both 
positions.
Discussion
Based on the results obtained, it appears that the studied 
sample was representative of the population for whom ChEI is 
routinely indicated, with a slightly higher prevalence of women 
(61.1%), as observed in a systematic review of Latin American 
population studies.32 This figure is almost identical to that 
found in a Spanish study, whose population of 1,940 patients 
was composed by 62% of women.33 The same study found 
a mean age of 77 years, which is the same observed in the 
present sample.
The mean score in the MMSE was within the range 
recommended for ChEI prescription,34 but it was slightly lower 
than that found in a study by Froelich et al.35 (19.7 points), 
possibly due to the lower educational level of the present 
Variables Mean SD Minimum
value
Maximum
value
HR (bpm) 70.4 11.8 48 108
Supine SBP (mmHg) 146.4 24.2 102 212
Supine DBP (mmHg) 80.0 9.2 58 102
Orthostatic SBP (mmHg) 145.5 23.6 106 214
Orthostatic DBP (mmHg) 79.0 12.4 46 108
bpm, beats per minute in the supine position; DBP, diastolic blood 
pressure; HR, heart rate; mmHg, millimeters of mercury; 
SBP, systolic blood pressure; SD, standard deviation.
Table 1 – Heart rate and blood pressure levels 
of the studied patients.
ECG alteration Number 
of patients
Left ventricular hypertrophy (Sokolow-Lyon index) 9
Left anterior-superior division block 7
Isolated ventricular extrasystoles 6
Nonspecific ventricular repolarization 5
First-degree atrioventricular block 5
Isolated atrial extrasystoles 5
Repolarization with pressure overload 3
Electrically inactive area 3
Anterolateral subepicardial ischemia 2
Complete left bundle branch block 2
Incomplete left bundle branch block 1
Complete right bundle branch block 1
Left atrial overload 1
Coupled atrial extrasystoles 1
Junctional extrasystole 1
ECG, electrocardiogram.
Table 2 – Electrocardiographic abnormalities detected.
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population. In the same German population study, the 
mean duration of symptoms until the start of therapy was 
15.8 months, significantly lower than that found in the present 
study (26.2 months). This is probably due to the difficulty in 
having access to appropriate treatment in the Brazilian public 
health system and to the lack of knowledge of the population 
about dementia symptoms and the existence of treatment. 
The percentage of patients who reported a positive family 
history for dementia was quite similar to that found by Zintl et 
al., whose study demonstrated that 39.5% of the 210 assessed 
patients had such history.36
Another important finding is related to the high prevalence 
of medical comorbidities, mainly hypertension, depression, 
diabetes mellitus, and hypothyroidism. These findings are 
consistent with those observed in a German population study 
in which 90% of the population had a clinical comorbidity, with 
a high prevalence of cardiovascular disorders in 53%, mental 
disorders in 27%, and endocrine-metabolic disorders in 27%.35 
Among the population studied by the latter authors,33 86% used 
other drugs (57% cardiovascular drugs and 40% psychotropic 
drugs), and these values are consistent with the present 
findings. The number of drugs used for the treatment of 
comorbidities was slightly lower than that observed in other 
studies, whose results vary from 5.1 to 5.8 drugs/patient.37,38
Nevertheless, it is emphasized that the routine use of other 
drugs in treatment regimens, which in the population studied 
comprised the use of up to eight drugs, raises the question of 
potential drug interaction dangers.39
The ECG showed the presence of significant alterations 
in some patients, which is consistent with the findings of a 
clinical trial with rivastigmine.40 Some of these alterations 
are considered as relative contraindications to the use of ChEI 
(such as atrioventricular block and complete bundle-branch 
block). For this reason, some specialists consider it prudent 
to request an electrocardiogram before prescribing the 
anticholinesterase therapy.1,41,42
The OH prevalence found in this population is consistent 
with those found in the studies by Ballard et al. and by 
Mehrabian et al., in which 14% of patients with dementia had 
OH.13,43 The finding of an association between MD and OH can 
be justified by the fact that these patients have, in addition 
to vasomotor center lesions resulting from AD, additional 
impairment of vascular origin. This is consistent with studies 
that showed a higher prevalence of autonomic dysfunction18 
and OH43,44 in VD compared to AD. Thus, although there were 
no studies in the literature that specifically evaluated MD 
in this regard, it is possible to infer that the vascular origin 
component of cognitive impairment is accompanied by ANS 
impairment. Accordingly, it has been shown that cognitive 
impairment and BP alterations mutually influence each 
other, i.e., neurodegenerative dementia processes lead to BP 
instability and alterations in cerebral perfusion can worsen 
brain lesions, consequently leading to cognitive impairment.43
There was a significant association between the presence of 
OH and lower values of LF and HF components in the spectral 
analysis in the supine position, and of LF in the orthostatic 
position. This may represent a causal association between ANS 
imbalance and prevalence of neurovascular instability of up 
to six times higher in patients with dementia,13 as well as an 
increased risk of falls.44
The ANS behavior during postural change showed no 
alteration in the isolated components with the orthostatic 
position, as observed in healthy subjects. There was a slight 
increase in LF and decrease in HF, both with no statistical 
significance, but a significant increase in LF/HF ratio, indicating 
the sympathetic predominance necessary to maintain BP on 
active orthostatic stress. 
These results are consistent with others reported in 
literature that show only borderline alterations in the 
ANS of dementia patients,18,19 in this case, represented by 
non-significant alterations in the individual components of 
HRV with the maintenance of sympathetic predominance in 
the orthostatic position. 
The main limitation of the present study was the relatively 
small sample size and the sample heterogeneity that, although 
fitting the purpose of representing the population attended to 
at the daily clinical practice, makes it difficult to draw more 
specific conclusions. There was no information regarding 
ion measurements and renal function, which may result in 
ECG changes, but all patients were stable from the clinical 
standpoint at the time of their assessment.
Conclusion
The profile of the patients in this study showed a predominance 
of the female gender, low educational level, and frequent 
presence of comorbidities, resulting in the concomitant use 
of several drugs. There was a long interval between symptom 
onset and diagnosis of dementia. An autonomic dysfunction 
picture was observed, resulting in orthostatic hypotension, 
mainly in patients with MD. 
These findings indicate the need to strive for earlier 
diagnosis and provide more explicit and accessible information 
to ensure proper understanding of the treatment. Additionally, 
greater caution is necessary when prescribing drugs that act on 
Supine position (mean ± SD) Orthostatic position (mean ± SD) p
LF (ms2) 319.3 ± 398.2 LF (ms2) 339.5 ± 514.8 0.758
HF (ms2) 1067.8 ± 3754.4 HF (ms2) 388.0 ± 1146.7 0.055
LF/HF 1.8 ± 2.1 LF/HF 3.2 ± 2.9 0.024
Recording time (min) 4.6 ± 0.6 Recording time (min) 4.4 ± 0.9  
HF, high-frequency component; LF, low-frequency component of heart rate variability; SD, standard deviation.
Table 3 – Spectral analysis of the autonomic nervous system of the patients in the supine and orthostatic positions.
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the ANS and the use of ChEI, in order to minimize undesirable 
drug interactions and decrease the risk of falls.
The study was approved by the Ethics Committee of UFMG 
on September 19, 2008, under No. 401/08. 
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